To be better prepared for the next pandemic, leading scientists from the Netherlands, Belgium and the United Kingdom are advocating some radical innovations. They propose the creation of a European authority for clinical research on pandemics to coordinate clinical research in this area thereby avoiding fragmentation of studies.

The pandemic has also shown that REMAP-CAP could do what it was designed for: Adapt in a pandemic, incorporate new promising interventions, adapt to a changing standard of care and quickly and effectively deliver results that change the clinical care of hospitalized and critically ill patients. Within 24 months of the start of the pandemic, we have been able to conclude on a total 7 domains and deliver 10 important conclusions for our patients.

We are proud to announce that REMAP-CAP is currently (7th June 2021) active in 320 sites in 22 countries worldwide and a total of 7,608 unique patients have been included, of which 6,766 COVID-19 patients. These patients contributed to a total of 13,747 randomisations in the different domains.